期刊文献+

多发性骨髓瘤的靶位治疗

原文传递
导出
摘要 多发性骨髓瘤(MM)是血液系统常见的恶性肿瘤,如何合理地治疗MM是提高缓解率延长生存期的关键。靶位治疗是针对骨髓微环境中MM细胞生长和生存的治疗,新的靶位治疗药物(沙利度胺、硼替佐米、来那度胺、砷剂等)联合传统的方法治疗MM已经取得突破性进展,这是当前治疗MM最有效的方法与途径。
出处 《国际输血及血液学杂志》 CAS 2010年第1期14-17,共4页 International Journal of Blood Transfusion and Hematology
  • 相关文献

参考文献13

  • 1Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood, 2008,111(5) :2516-2520.
  • 2Anderson KC. Multiple myeloma., advances in disease biology, therapeutic implication. Semin Hematol,2001,38(2 suppl 3):6- 10.
  • 3Hayashi T, Hideshima T, Akiyama M, et al. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther, 2002,1 (10): 851- 860.
  • 4Rajkumar SV. Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myetoma: A clinical trial coordinated by the Eastern cooperative Oncology Group. J ClinOncol, 2006,24(3):431-436.
  • 5Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet, 2006, 367 (9513):825- 831.
  • 6Facon T, Mary J, Harousseau J, et al. Superiority of melphalan-prednisone (MP) + thalidomide (THAI.) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. J Clin Oncol, 2006,24:1s, Abstract 1.
  • 7Hazarika M, Rock E, Williams G, et al. l.enalidomide in Combination with Dexamethasone for the Treatment of Multiple Myeloma After One Prior Therapy . Oncologist, 2008, 13(10) : 1120 -1127.
  • 8Richardson PG, Barlogie B, Berenson J, et al. Extended follow up of a phase II trial in relapsed, refractory multiple myeloma, final time to event results from the SUMMIT trial. Cancer, 2006,106 (6):1316-1319.
  • 9Richardson PG, Sonneveld P, Schuster M,et al. Extended follow- up of a phase 3 trial in relapsed multiple myeloma: final time-to- event results of the APEX trial. Blood, 2007,110(10):3557- 3560.
  • 10钟玉萍,陈世伦.硼替佐米治疗复发难治性多发性骨髓瘤43例[J].白血病.淋巴瘤,2009,18(9):538-540. 被引量:6

二级参考文献12

  • 1邱录贵.多发性骨髓瘤的发病与国人特点[J].中国实用内科杂志:临床前沿版,2006,26(6):886-888. 被引量:52
  • 2Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood, 2004, 103: 20-32.
  • 3Bataille R. Harousseau JL. Multiple myeloma. The New England Journal of Medicine, 1997, 336: 1657-1664.
  • 4The UK Myeloma Forum Guidelines Working Group.Diagnosis and management of multiple myeloma. Bri J Haematol, 2001, 115: 522-540.
  • 5Blad e, J, Samson D, Reeee D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT.European Group for Blood and Marrow Transplant. Br J Haematol. 1998. 102:1115-1123.
  • 6Popat R, Oakervee H, Williams C, et al. Bortezomid,low-dose intravenous melphalan,and dexamethasone for patients with relapsed muhiple myeloma. Br J Haematol, 2009, 144: 887-894.
  • 7Podar K, Tai YT, Hideshima T, et al. Emerging therapies for multiple myeloma. Expert Opin Emerg Dnlgs, 2009, 14: 99-127.
  • 8Berenson JR, Yang HH, Vescio RA, et al. Safety and efficacy of bortezomid and melphalan combination in patients with relapsed or refractory multiple myeloma:updated results of a phase 1/2 study after longer follow-up. Ann Hematol, 2008, 87:623-631.
  • 9BladeJ, Sonneveld P, San Miguel JF, et al. Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory. muhiple myeloma: efficacy and safety in patients with renal function impairment. Clin Lymphoma Myeloma, 2008, 8: 352-355.
  • 10钟玉萍,陈世伦,李新,张佳佳,安娜.硼替佐米联合其他药物治疗30例多发性骨髓瘤患者的临床观察[J].中华内科杂志,2008,47(2):137-138. 被引量:7

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部